Faculty Interviews from the 29th Annual International Prostate Cancer Update On The Role of Genotypic and Phenotypic Biomarkers in Prostate Cancer David M. Albala, MDCrouse Hospital and Associated Medical ProfessionalsSyracuse,...
Read More
David M. Albala, MD, emphasizes the need for improved prostate cancer diagnostics to allow for better risk-stratification and guidance of personalized treatment. He then reviews findings from an analytical validation study of live-primary cell phenotypic biomarker-based diagnostic assay with the potential to address this need
Read More
Paul D. Maroni, MD, argues that salvage pelvic lymph node dissection is feasible, safe, and may be efficacious in the treatment of oligometastatic prostate cancer. He reviews data suggesting that this method can optimize locoregional control, limit the risk of distant progression, avoid the necessity for immediate androgen deprivation therapy (ADT), and improve cancer-specific survival.
Read More
James Sylora, MD, discusses the increasing demand for telemedicine services and the advantages it provides to patients and clinical practices. He outlines steps, as well as practical and legal considerations, for establishing a telemedicine protocol in a practice.
Read More
Mohit Khera, MD, MBA, MPH, reviews current practices for treatment of erectile dysfunction, including timing of therapy after radical prostatectomy, risk factors for penile rehabilitation, and the current American Urological Association (AUA) guidelines.
Read More